Amicus Therapeutics Is Always Searching For New Treatments

Amicus Therapeutics, Inc. refers to a biotechnology firm having a global network. It likes to remain ahead in terms of providing advanced therapies. This way it aims at treating various rare as well as orphan diseases that can be devastating. This is not all. They pride themselves on having a robust pipeline that comprises of new treatments being developed for several genetic diseases.


Their lead product is migalastat. It is in its last stage of development. It can treat individuals suffering from Fabry disease. This can be done through the genetic diagnosis. Another product is SD-101. This is also in its later stages of development. This will be a first-of-its-kind of therapy to be marketed for the connective tissue disorder known as Epidermolysis Bullosa (EB). It is a rare genetic disorder. Amicus Therapeutics has a biologics along with Chaperone-Advanced Replacement Therapy platform. They are leveraging this for developing various products for its enzyme replacement therapy. These can be used for Fabry disease, as well as Pompe disease, along with several Lysosomal Storage Disorders.

Amicus Therapeutics offers Patient & Professional Advocacy. This is designed for collaborating with several patient organizations, as well as individual patients, along with their caregivers, as well as healthcare practitioners. This is an effort for ensuring that Amicus Therapeutics is doing all that it possibly can in order to support this community related to rare diseases (GoogleFinance). They wish to provide those initiatives which can bring purpose along with empowerment. This way Amicus Therapeutics will help to ease the difficulties that are being faced by the members of this rare disease community.


The aim of the Advocacy program is that Amicus Therapeutics wants to serve as the bridge that links the patients, the families, along with other resources. This way they are trying to offer unprecedented access to support as well as other services that can ease their disease experience.


All this indicates the dedication of Amicus Therapeutics to patients as well as their families. Hence they are committed to providing healing that goes beyond disease. In order to do so, Amicus Therapeutics listens as well as learns from individuals who are affected by such diseases in order to provide better therapies.

More about Amicus Therapeutics on



The Incident That Started The Larkin & Lacey Frontera Fund

There are many different people who will find that they need help because they are of Mexican descent, and they are often trapped in Arizona because the law enforcement is against them as people. There was an arrest that was started by Joe Arpaio to stop his critics from unearthing evidence that he was obstructing the first amendment. He is one of the worst advocates of conservatism, and he had to pay nearly $4 million in a settlement after the settlement. This article shows how the fund has come to grow since it started.


#1: The Incident Turned On The Sheriff


There are many people who will find that it is easy to get help from the fund when they need it. Jim Larkin and Michael Lacey started the fund because they wanted to help all Mexican immigrants and other people of color. It is quite interesting to ensure that these people have been given help, and there are many people who will notice that they may fight back against poor law enforcement.


#2: The Frontera Fund Is Growing


The Frontera Fund is growing because of the other events that they are holding, and they want to ensure that there are many people who will have money and resources that will help them. These people may be bailed out of jail, and they may be given legal assistance when needed. It is easy for someone to meet a professional from the fund, and they will have assistance that helps them get out of jail and fight for their rights.


#3: Arizona Must Change


Jim and Michael believe that Arizona must change if it will be a better place to live, and they are hoping to see the state alter its course by helping people who need it the most. Jim and Michael has written about injustice for years, and they now use their experience reporting on injustice to change lives. They ensure that the nonprofit will have a greater reach, and they will find that there are many people who come forward due to allegations that may be older. Jim and Michael want to serve all people who need help, and they want to provide the services that are required to those who cannot help themselves.


Anyone who is searching for a better way to help the voiceless may turn to the Frontera Fund, and they have a number of things that will help people with legal assistance and aid with law enforcement. Someone who has been oppressed in the past will find that they need a partner who will help them, and this fund is the only place to come for consistent care when the government oversteps its bounds.


Amicus Therapeutics: A Bio-pharmaceutical Company Dealing Mainly With Chaperone

Amicus Therapeutics went public in the year 2007. Before that, it was sourcing its funding from a variety of Venture Capital firms. The company was founded on February 4th, in the year 2002. It’s located in the State of New Jersey.

The company mainly has developed a focus revolving around lysosomal storage disorders and other rare orphan diseases. The company mainly develops its pharmaceutical products based on Chaperone-Advanced Replacement Therapy commonly known as CHART. It has also focused on coming up with Enzyme Replacement Therapies (ERTs). Interesting to note, in the year 2014, the company, Amicus bio-pharmaceuticals was considered as being in possession of a wide range of small molecule pharmacological chaperones among the pharmaceutical industries.


For instance, the company had sold a pharmacological chaperone treatment for Fabry Disease commonly known as migalastat which used the trade name of Galafold. The drug mainly is used to make endogenous mutant alpha-galactosidase stable. Amicus Therapeutics has also partnered with other pharmaceutical companies such as GlaxoSmithKline (gsK) and JCR Pharmaceutical from the year 2010 to 2013 to research and deeply study about the co-formulation with recombinant alpha-galactosidase.


Amicus Therapeutics encountered financial challenges in the year 2009 when one of its funding partner, Shire, ended a contract. After that, Amicus Therapeutics faced significant setbacks although it managed to survive by all means necessary using funds from the initial contract with Shire. The firm was also forced to lay off some of the workers. For instance, about 20 percent of the total workforce was reduced.


In the year 2013, Amicus Therapeutics successfully purchased Callidus Biopharma which was mainly focused on developing therapy treatment for Pompe disease. Callidus Biopharma was the main competitor of Amicus Therapeutics. The purchase meant that proprietary materials and intellectual property of Callidus bio pharma now belonged to Amicus therapeutics.


The CEO of the company has been John F. Crowley since the year. Through his exquisite managerial skills, he has been able to lead the firm through financial challenges. Amicus Therapeutics has been able to grow exponentially over the years. Its specialty in chaperone related therapeutics has made the firm earn recognition.


More Here:  Facebook | Crunchbase | Twitter |

Success Academy launches a free online portal

Founded by Eva Moskowitz who is also the Chief Executive Officer, Success Academy is the New York City’s largest charter school network began a decade ago, Moskowitz had two goals: Start top-performing schools as well as work towards improving the American education system.


The CEO has undertaken an ambitious plan to expand Success Academy with the new online platform. The platform aimed at growing the institution’s network footprint ahead of the largest district school in America.


The free portal unveiled by Moskowitz and other Success Academy leaders from their headquarters in Lower Manhattan was dubbed the “Success Academy Education Institute.” The portal provides access to teacher development strategies as well as employing the curriculum at the 41 schools of Success Academy across the city.


Eva Moskowitz noted that many kids across the country are in schools where they are not taught to read or write as well as do mathematics and science at the core level. As a result, Success Academy was destined to be part of the solution.


Success Academy’s track record speaks volumes. The institution closed the achievement gap and improved the academic outcomes of low-income students. As a result, the school won the $250,000 Broad Prize meant for college preparedness programs that include scholarships and campus visits.


The online platform provides the charter network’s literacy curriculum for kindergarten to the fourth grade. It was the initial step to introduce teachers to the Success Academy mantra across the country. Besides, the network has a plan to launch a teacher-training facility at Hudson Yards in Manhattan and a school lab for students in kindergarten through eighth grade.


Success Academy is where 76 percent of the over 14,000 students are low-income, and 93 percent are African-American. Also, its middle and elementary schools were amongst the top 10 percent of campuses statewide on math, English, as well as science tests the previous year.


The Success Academy chief academic officer, Michele Caracappa said that if the institution could have had one resource, then it would have been the books. He adds that they had spent countless hours hand-picking the books for Success Academy.

College Admissions: What Every High School Scholar — and Parent — Should Know